GA39855: A prospective, randomized, double blind placebo controlled, parallel group study to determine the efficacy and safety of omalizumab compared with placebo in adult patients with chronic rhinosinusitis with nasal polyps who have had an inadequate response to standard of care treatments.
Past Project
